OCON Medical Ltd.

Based in Israel, OCON Therapeutics specializes in innovative intrauterine drug-delivery technologies aimed at enhancing women's health and quality of life. This company develops advanced medical devices focused on women's reproductive health. OCON Therapeutics, founded in 2011 in Modiin, Israel, is dedicated to improving women's health through innovative intrauterine technologies. The company has engaged in one significant funding round, securing USD 10.

000 mn in June 2024, led by RHV Capital, alongside investors such as Astia Angels and Features Capital. Keren Leshem serves as the CEO, driving the company’s mission to enhance therapeutic solutions for women. OCON Therapeutics specializes in innovative intrauterine drug-delivery technologies aimed at enhancing women's health and quality of life. Their flagship product, the IUB® Ballerine®, is a next-generation, hormone-free intrauterine device (IUD) designed to fit women's anatomical structures comfortably while providing long-acting reversible contraception.

In addition to the Ballerine®, OCON offers the IUB® SEAD®, a spherical endometrial ablation device that presents a novel solution for treating abnormal uterine bleeding (AUB) and heavy menstrual bleeding (HMB). The IUB® PRIMA® is also part of their product line, targeting conditions such as endometriosis and myomas through targeted therapeutic delivery directly to the uterus. These products are primarily marketed to healthcare providers and gynecologists across various geographical markets, including Europe and non-U. S.

regions, where they aim to improve patient outcomes in women's health. The revenue model for OCON Therapeutics is structured around direct sales of its proprietary medical devices to healthcare providers and medical facilities, focusing on gynecological practices. Transactions typically occur through business-to-business (B2B) agreements, where hospitals and clinics purchase devices such as the IUB® Ballerine® and IUB® SEAD® to incorporate into their treatment offerings. Pricing structures are determined on a case-by-case basis, reflecting the clinical value provided by these advanced medical solutions.

The company's revenues are driven not only by the sales of these flagship products but also by ongoing clinical partnerships and potential future collaborations that may emerge as the therapeutic landscape evolves. In June 2024, OCON Therapeutics raised USD 10. 000 mn in venture funding led by RHV Capital, with participation from Features Capital, Astia Angels, Exerte Partners, and the Israel Innovation Authority. The funding will be utilized to develop innovative solutions for common uterine disorders, aiming to establish a safer standard of care using its proprietary 3D drug delivery system.

The company is focused on expanding its product offerings and entering new international markets to enhance its reach and impact in women's health.